Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Urologe A ; 55(1): 27-34, 2016 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-26676728

RESUMO

BACKGROUND: Vesico-ureteral reflux (VUR) is one of the most common urologic diseases in childhood. About every third child that presents with a urinary tract infection (UTI) has urinary reflux to the ureter or kidney. Demonstration of a backflow of urine into the ureters or kidneys proves vesicoureteral reflux. In unclear cases, a positioned instillation of contrast agent (PIC) cystogram might be performed and is able to prove vesico-ureteral reflux. OBJECTIVES: Since low-grade VUR has a high probability of maturation and self-limitation, infants with VUR should be given prophylactic antibiotics during their first year of life, reevaluating the status of VUR after 12 months. The aim of any treatment is to prevent renal damage. THERAPY: The individual risk of renal scarring is decisive for the choice of adequate therapy. This risk is mainly dependent on reflux grade, age, and gender of the child as well as parental therapy adherence. In principle, therapeutic options include conservative as well as endoscopic or open surgical antireflux therapies. CONCLUSION: Decisions on treatment should be made individually with parents taking into account all the findings available.


Assuntos
Endoscopia/normas , Infecções Urinárias/diagnóstico , Infecções Urinárias/tratamento farmacológico , Urografia/normas , Refluxo Vesicoureteral/diagnóstico , Refluxo Vesicoureteral/terapia , Antibacterianos/uso terapêutico , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Guias de Prática Clínica como Assunto , Resultado do Tratamento , Infecções Urinárias/complicações , Procedimentos Cirúrgicos Urológicos/normas , Refluxo Vesicoureteral/etiologia
2.
Urologe A ; 53(7): 1031-9, 2014 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-24957523

RESUMO

In Europe prostate cancer is one of the most common cancers among men. The diagnostics always include a control of the prostate-specific antigen (PSA) level and examination of a representative tissue sample from the prostate. With these findings it is possible to evaluate the degree of progression of the cancer and its prognosis. Several treatment options for localized prostate cancer are given by national and international guidelines including radical prostatectomy, percutaneous radiation therapy, or brachytherapy and surveillance of the cancer with optional treatment at a later stage. For the latter treatment option, known as active surveillance, strict criteria have to be met. The advantage of active surveillance is that only patients with progressive cancer are subjected to radical therapy. Patients with very slow or non-progressing cancer do not have to undergo therapy and thus do not have to suffer from the side effects. The basic idea behind active surveillance is that some cancers will not progress to a stage that requires treatment within the lifetime of the patient and therefore do not require treatment at all. Unfortunately the criteria for active surveillance are not definitive enough at the current time leading only to a delay in effective treatment for many patients. The surveillance strategy has without doubt a high significance among the treatment options for prostate cancer; however, at the current time it lacks reliable indicators for a certain prognosis. Therefore, patients must be informed in detail about the advantages and disadvantages of active surveillance.


Assuntos
Biomarcadores Tumorais/sangue , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia , Conduta Expectante/métodos , Medicina Baseada em Evidências , Humanos , Masculino , Prognóstico , Neoplasias da Próstata/sangue , Medição de Risco/métodos
3.
Urologe A ; 53(9): 1310-5, 2014 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-25113827

RESUMO

Primary urethral carcinomas are rare tumors that can occur both in men and women. Histological patterns of these tumors are mixed, urothelial tumors occur as well as squamous cell tumors or adenocarcinomas.There are different clinical factors that define clinical prognosis, and the 1- and 5-year cancer-free survival is 75% and 54%. Therapy of locally limited disease is surgical resection, and organ-preserving treatment is possible if negative frozen sections prove complete surgical resection. However, in men a perineal urethrostomy might be necessary, and in women there is a high risk of urinary incontinence if more than 2 cm of the distal urethra is resected.In case of locally advanced tumors or tumors of the proximal urethra, a radical urethrectomy with supravesical urinrary diversion is necessary. In some cases neoadjuvant (radio-)chemotherapy may be an option.


Assuntos
Antineoplásicos/uso terapêutico , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Tratamentos com Preservação do Órgão/métodos , Órgãos em Risco/cirurgia , Neoplasias Uretrais/terapia , Procedimentos Cirúrgicos Urológicos/métodos , Quimioterapia Adjuvante/métodos , Feminino , Humanos , Masculino , Recuperação de Função Fisiológica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA